Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction. Pluripotent stem cells can be generated from the somatic cells of humans and are a useful model to study disease. Here, pluripotent stem cells are made from a patient with familial Parkinson's disease, and the resulting neurons exhibit elevated levels of α-synuclein, recapitulating the molecular features of the patient's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SNCA triplication patient iPSC-derived dopaminergic neurons showed α-synuclein protein over accumulation which was consistent with pathological phenotype in PD patient [35].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Efficient Derivation of Functional Floor Plate Tissue from Human Embryonic Stem Cells
Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J., & Studer, L. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.001 · Cited by 209 · cited 1×
“The dual SMAD inhibition protocol has been employed to generate floor plate tissue from human ESC”
MethodRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“A potential solution is to utilize reprogamming technology to generate disease-specific induced pluripotent stem cells (iPSCs”
BackgroundAnalyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“Results were normalized to human TBP using the comparative C(T) metho”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Self-citationHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“Directed differentiation to dopaminergic neurons We used a feeder-free monolayer culture method of inducing neural differentiation under defined conditions, via dual inhibition of SMAD signallin”
Method
Cited by
Items 301–400 of 484
Shrigley, S., Nilsson, F., Mattsson, B., Fiorenzano, A., Mudannayake, J. M., Bruzelius, A., Ottosson, D. R., Björklund, A., Hoban, D. B., & Parmar, M. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202366 · Cited by 16
“However, other studies have reported that patient cell lines with Syn mutations differentiate with the same efficiency as healthy cell lines regardless of the SNCA genotype [22, 26, 35].”
BackgroundMethodResultInfluentialDambrot, C., Buermans, H. P. J., Varga, E., Kosmidis, G., Langenberg, K. P. S., Casini, S., Elliott, D. A., Dinnyés, A., Atsma, D. E., Mummery, C. L., et al. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.05.001 · Cited by 15
Singh, S., Srivastava, A., Srivastava, P., Dhuriya, Y. K., Pandey, A., Kumar, D., & Rajpurohit, C. S. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00072 · Cited by 16
“Animal and cellular models have given us a deep understanding of the disease but data generated is not fully applicable to human subjects due to difference in disease pathogenesis of animals and humans (Devine et al., 2011).”
BackgroundChen, S.-D., Li, H., Cui, M., Dong, Q., & Yu, J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1767579 · Cited by 15
Targeting cell plasticity for regeneration: From in vitro to in vivo reprogramming
Romanazzo, S., Lin, K., Srivastava, P., & Kilian, K. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.007 · Cited by 17
“Significant numbers of observational clinical studies have been conducted on disease modelling and drug discovery with iPSCs, including amyotrophic lateral sclerosis (ALS) [199,200], Alzheimer’s disease [201,202], Parkinson disease [203,204], long QT syndrome [94,205], and CF [206,207].”
BackgroundFreeman, D. M., & Wang, Z. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00627 · Cited by 14
Vetchinova, A. S., Рафаилевна, К. М., Ivanov, M. V., Kutukova, K. A., Mudzhiri, N. M., Frumkina, L. E., Васильевич, Б. А., Sukhorukov, V. S., & Illarioshkin, S. N. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100529 · Cited by 16
“…for phosphorylated α -synuclein in LRRK2 cells of the line with a mutation in the gene is associated with a high content of immature neurons in this cell culture [30]. cells of the line with a mutation in the (2011) showed a similar pattern of immunofluorescent staining for α -synuclein [27].”
BackgroundHuman pluripotent stem cells on artificial microenvironments: a high content perspective
Viswanathan, P., Gaskell, T. L., Moens, N., Culley, O. J., Hansen, D. M., Gervasio, M. K. R., Yeap, Y. J., & Danovi, D. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00150 · Cited by 14
“Cells reprogrammed from a patient that showed triplication of the alpha-synuclein locus and their comparison with those derived from an unaffected first-degree relative represent a significant step forward (Devine et al., 2011).”
ResultInduced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling
Zhu, D., Kong, C. S. L., Gingold, J. A., Zhao, R., & Lee, D. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_257 · Cited by 15
Maor, G., Dubreuil, R. R., & Feany, M. Β. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1922-22.2022 · Cited by 14
Heng, B. C., Saxena, P., & Fussenegger, M. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.01.021 · Cited by 13
Roessler, R., Boddeke, E., & Copray, S. C. V. M. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-012-9369-4 · Cited by 13
Borlongan, C. V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807276115 · Cited by 12
Mishima, T., Fujioka, S., Fukae, J., Yuasa‐Kawada, J., & Tsuboi, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123870 · Cited by 13
“iPSCs were generated from an SNCA triplication patient and differentiated into DA neurons [38].”
BackgroundMethodInduced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
Sánchez‐Danés, A., Benzoni, P., Memo, M., Dell`Era, P., Raya, Á., & Consiglio, A. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152731131200128 · Cited by 12
Eglen, R. M., & Reisine, T. (2018) · SLAS TECHNOLOGY · doi:10.1177/2472630318803277 · Cited by 11
“One of the first HiPSC models of PD involved the generation of dopamine neurons from PD patients possessing the aSYN triplication mutation.(113) The neurons expressed increased levels of aSYN and increased sensitivity to oxidative stressors that induced neurodegeneration.”
BackgroundVroman, R., de Lichtervelde, L., Dolt, K. S., Robertson, G., Kriek, M., Barbato, M., Cholewa-Waclaw, J., Kunath, T., Downey, P. M., & Zagnoni, M. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00936-x · Cited by 12
“Human iPSC-derived midbrain dopaminergic neuronal differentiation The AST18 hiPSC line, derived from a patient with a triplication of SNCA , encoding α Syn 44 , wasused forthedifferentiationofmidbraindopaminergic (mDA) neurons.”
InfluentialSelf-citationTargeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models
Spathopoulou, A., Edenhofer, F., & Fellner, L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.786835 · Cited by 12
Fukusumi, H., Togo, K., Sumida, M., Nakamori, M., Obika, S., Baba, K., Shofuda, T., Ito, D., Okano, H., Mochizuki, H., et al. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.13060 · Cited by 13
Langlie, J. A., Mittal, R., Finberg, A., Bencie, N. B., Mittal, J., Omidian, H., Omidi, Y., & Eshraghi, A. A. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335836 · Cited by 10
“Devine et al., 2011 Parkinson’s disease iPSCs Fibroblast derived iPSCs – G2019S-LRRK2 mutation • Mutated G2019S-LRRK2 iPSCs demonstrated the increased generation of alpha-synuclein protein and increased expression of oxidative stress-response genes.”
BackgroundAkrioti, E.-K., Karamitros, T., Gkaravelas, P., Kouroupi, G., Matsas, R., & Taoufik, E. (2022) · Biomolecules · doi:10.3390/biom12070876 · Cited by 10
Human Stem Cells for Craniomaxillofacial Reconstruction
Jalali, M., Kirkpatrick, W. N. A., Cameron, M. G., Pauklin, S., & Vallier, L. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0576 · Cited by 11
Induced Pluripotency for Translational Research
Wu, M., Chen, G., & Hu, B. (2013) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2013.08.001 · Cited by 10
“A variety of patient-specific hiPSCs from Parkinson’s disease (PD) [34], Alzheimer’s disease (AD) [35–37], Huntington’s disease (HD) [38] and schizophrenia [39] patients have been obtained and have all been shown competent to model the disease progression in vitro.”
BackgroundKiris, E. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_683 · Cited by 10
Florido, M. H. C., & Ziats, N. P. (2024) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37669 · Cited by 9
Tripathi, A., Alnakhala, H., Brontesi, L., Selkoe, D. J., & Dettmer, U. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05373-2 · Cited by 9
“A) along with the isogenic CRISPR-corrected control line (#EDi0001-A4), in which the start codon of two copies of the SNCA gene had been disrupted by CRISPR/Cas [18, 58].”
Jendelová, P., Syková, E., & Erceg, S. (2018) · Results and problems in cell differentiation · doi:10.1007/978-3-319-93485-3_3 · Cited by 9
A Preview of Selected Articles
Atkinson, S. P. (2017) · Stem Cells · doi:10.1002/stem.2745 · Cited by 9
Reactive astrocytes generated from human iPSC are pro-inflammatory and display altered metabolism
McComish, S. F., O’Sullivan, J., Copas, A. N. M., Imiolek, M., Boyle, N. T., Crompton, L. A., Lane, J. D., & Caldwell, M. A. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114979 · Cited by 11
Borah, R., O'Sullivan, J., Spurling, D., McLoughlin, A., Sanchez-Amador, D. E., Suku, M., Nicolosi, V., Motta, A., Caldwell, M. A., & Monaghan, M. G. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124079 · Cited by 12
Unraveling the Complex Interplay between Alpha-Synuclein and Epigenetic Modification
Sugeno, N., & Hasegawa, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076645 · Cited by 8
Liu, J., Ji, Z., He, Q., Chen, H., Xu, X., Mei, Q., Hu, Y., & Zhang, H. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106683 · Cited by 9
“For instance, dopaminergic neurons from iPSCs in PD patients produce twice as much α -synuclein as those from normal donors, and they exhibit significant differences in neuronal maturation (Devine et al., 2011).”
A compendious summary of Parkinson’s disease patient-derived iPSCs in the first decade
Ren, C., Wang, F., Guan, L.-N., Cheng, X.-Y., Zhang, C.-Y., Geng, D., & Liu, C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.16 · Cited by 9
Regenerative Medicine for Parkinson’s Disease
Yasuhara, T., Kameda, M., Agari, T., & Date, I. (2015) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2014-0264 · Cited by 10
Cellular reprogramming: A new way to understand aging mechanisms
İlçe, B. Y., Cagin, U., & Yılmazer, A. (2018) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.308 · Cited by 8
“This also exists in DA neurons generated from iPSCs from patients with an SNCA locus triplication. iPSC-derived DA neurons of patients produce double the amount of α-synuclein protein when compared with controls (Byers et al., 2011; Devine et al., 2011).”
ResultVolta, M., Lavdas, A. Α., Obergasteiger, J., Überbacher, C., Picard, A., Pramstaller, P. P., Hicks, A. A., & Corti, C. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.11.012 · Cited by 9
Drouin‐Ouellet, J., & Barker, R. (2012) · Stem Cells International · doi:10.1155/2012/926147 · Cited by 9
Chedid, J., Li, Y., Labrador‐Garrido, A., Abu-Bonsrah, K. D., Pavan, C., Fraser, T. D., Ovchinnikov, D. A., Zhong, M., Davis, R. L., Strbenac, D., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01048-2 · Cited by 9
Human stem cell-derived ventral midbrain astrocytes exhibit a region-specific secretory profile
Crompton, L. A., McComish, S. F., Steward, T. G. J., Whitcomb, D. J., Lane, J. D., & Caldwell, M. A. (2023) · Brain Communications · doi:10.1093/braincomms/fcad114 · Cited by 6
Stem Cell-Based Approaches in Parkinson's Disease Research
Kim, M. S., Yoon, S., Choi, J., Kim, Y. J., & Lee, G. (2024) · International Journal of Stem Cells · doi:10.15283/ijsc23169 · Cited by 9
“A significant emphasis within the realm of hiPSC models lies in the exploration of α -syn ( SNCA ) mutations and gene multiplications associated with PD (4, 84-86).”
Esteban, P. P., Patel, H., Veraitch, F. S., & Khalife, R. (2021) · Biotechnology Progress · doi:10.1002/btpr.3143 · Cited by 7
CHIP-dependent regulation of the actin cytoskeleton is linked to neuronal cell membrane integrity
Dias, C., Nita, E., Faktor, J., Tynan, A. C., Hernychová, L., Vojtěšek, B., Nylandsted, J., Hupp, T. R., Kunath, T., & Ball, K. L. (2020) · iScience · doi:10.1016/j.isci.2021.102878 · Cited by 8
Self-citationStem cell reprogramming: Basic implications and future perspective for movement disorders
Brändl, B., Schneider, S. A., Loring, J. F., Hardy, J., Gribbon, P. M., & Müller, F. (2014) · Movement Disorders · doi:10.1002/mds.26113 · Cited by 9
Self-citationDopaminergic differentiation using pluripotent stem cells
Momčilović, O., Montoya‐Sack, J., & Zeng, X. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24251 · Cited by 9
“For example, iPSC lines have been derived from patients harboring LRRK2 G2019S mutation [Nguyen et al., 2011], alpha-synuclein triplication [Byers et al., 2011; Devine et al., 2011], PARK2 mutations [Jiang et al., 2012], as well as from patients with sporadic PD [Soldner et al., 2009].”
BackgroundInducible Alpha-Synuclein Expression Affects Human Neural Stem Cells' Behavior
Zasso, J., Ahmed, M., Cutarelli, A., & Conti, L. (2018) · Stem Cells and Development · doi:10.1089/scd.2018.0011 · Cited by 7
Jung‐Klawitter, S., & Opladen, T. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0225-9 · Cited by 9
“…neurons Koch et al. 2011 Parkinson’s disease LRKK2, PINK1, SNCA, PARKIN, sporadic Dopaminergic neurons Soldner et al. 2009; Cooper et al. 2010, 2012; Devine et al. 2011; Nguyen et al. 2011; Seibler et al. 2011; Imaizumi et al. 2012; Jiang et al. 2012; Rakovic et al. 2013; Sánchez-Danés et al.…”
BackgroundThe Potential of iPS Cells in Synucleinopathy Research
Linta, L., Stockmann, M., Boeckers, T. M., Kleger, A., & Liebau, S. (2012) · Stem Cells International · doi:10.1155/2012/629230 · Cited by 7
α-synuclein pathogenesis in hiPSC models of Parkinson’s disease
Baena-Montes, J. M., Avazzadeh, S., & Quinlan, L. R. (2021) · Neuronal Signaling · doi:10.1042/ns20210021 · Cited by 7
Samson, J. S., Ramesh, A., & Parvathi, V. D. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.03.025 · Cited by 6
White, A. J., Clark, K. A., Alexander, K. D., Ramalingam, N., Young‐Pearse, T. L., Dettmer, U., Selkoe, D. J., & Ho, G. P. H. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00725-y · Cited by 6
“The SNCA triplication and corrected iPSC lines (AST23) wereobtainedthroughEBISCthankstoagenerousgiftfromtheKunathlab (UniversityofEdinburgh) 31 .”
Biologically inspired heterogeneous learning for accurate, efficient and low-latency neural network
Wang, B., Zhang, Y., Li, H., Dou, H., Guo, Y., & Deng, Y. (2024) · National Science Review · doi:10.1093/nsr/nwae301 · Cited by 11
“For example, the Sncg cell type has been reported in neurotic pathology of multiple system atrophy [30 ], the Serpinf1 is downregulated in primary malignant brain tumor [31 ] (i.e. glioblastoma) and the Astro deletion reduces the brain edema [32 ].”
InfluentialRaza, A., Raina, J., Sahu, S. K., & Wadhwa, P. K. (2025) · Neurological Sciences · doi:10.1007/s10072-024-07970-2 · Cited by 7
“Moreover, the review underscores the differential effects of LRRK2 kinase inhibitors, including GNE-7915, between LRRK2 mutated neurons and those with SNCA triplication [107, 108].”
Genome editing in stem cells for genetic neurodisorders
Dell’Amico, C., Tata, A., Pellegrino, E., Onorati, M., & Conti, L. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.006 · Cited by 6
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Chigurupati, S., Felemban, S. G., Alsubaiyel, A. M., Iqbal, M. S., Bhatia, S., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10390-4 · Cited by 6
Lv, Y., Qin, Y. F., Wang, J., Tian, G., Wang, W., Cao, C., & Zhang, Y. (2023) · BMC Genomics · doi:10.1186/s12864-023-09285-6 · Cited by 6
Paschou, C., Apokotou, O., Charmpi, K., Kollias, A., Dede, S., Samiotaki, M. K., Koutsoudaki, P. N., Havaki, S., Palese, F., Dimoula, K., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505240122 · Cited by 6
The Quest for Anti-α-Synuclein Antibody Specificity—Lessons Learnt From Flow Cytometry Analysis
Leupold, L., Sigutova, V., Gerasimova, E. M., Regensburger, M., Zundler, S., Zunke, F., Xiang, W., Winner, B., & Prots, I. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.869103 · Cited by 5
“We utilized HEK cells, which have been reported to have high aSyn expression (45), hiPSC with moderate levels of aSyn protein, as well as human fibroblasts and T cells expressing rather low aSyn levels (46, 47).”
MethodStem cells and regenerative therapies for Parkinson’s disease
Barker, R. A., & Farrell (2012) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s16087 · Cited by 9
Stem cell models of Alzheimer's disease and related neurological disorders
Livesey, F. J. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt147 · Cited by 6
Stem Cell Technology for (Epi)genetic Brain Disorders
Riemens, R. J. M., Soares, E. S., Esteller, M., & Delgado‐Morales, R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_23 · Cited by 8
Malpass, K. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.144 · Cited by 5
Chung, Y. G., Seay, M., Elsworth, J. D., & Redmond, D. E. (2020) · Stem Cells and Development · doi:10.1089/scd.2020.0059 · Cited by 5
Cao, D., Cheung, H., & Chan, W. (2019) · Stem Cells and Development · doi:10.1089/scd.2018.0209 · Cited by 9
First trials test targeting of α-synuclein for Parkinson disease
Kalia, L. V. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00726-6 · Cited by 5
The Role of Structural Variants in the Genetic Architecture of Parkinson’s Disease
Miano‐Burkhardt, A., Jerez, P. Á., Daida, K., Bandrés‐Ciga, S., & Billingsley, K. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094801 · Cited by 4
“…the functional effects of these multiplications, particularly the triplication, in vitro and post-mortem. iPSCs derived from patients with an SNCA triplication recapitulate the accumulation of alpha-synuclein and doubling of gene expression [48] as seen in post-mortem blood and brain samples [49].”
BackgroundPistollato, F., Furtmann, F., Gastaldello, A., Pastorino, R., Petra, E., Tripodi, I. J., & Constantino, H. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07019-8 · Cited by 5
“By differentiating iPSCs into brain cell types and leveraging co-culture platforms, researchers can gain critical insights into cell-type-specific dysfunctions associated with aging [82–84], and neurodegenerative diseases, such as Alzheimer’s disease [85], and Parkinson’s disease [86, 87].”
Converted neural cells: induced to a cure?
Zhang, W., Duan, S., Li, Y., Xu, X., Qu, J., Zhang, W., & Liu, G.-H. (2012) · Protein & Cell · doi:10.1007/s13238-012-2029-2 · Cited by 4
“…and neurodegenerative diseases, identify candidate pathogenic genes, and screen potential drugs (Marchetto et al., 2010; Brennand et al., 2011; Devine et al., 2011; Dolmetsch and Geschwind, 2011; Grskovic et al., 2011; Han et al., 2011; Kim et al., 2011c; Koch et al., 2011; Nguyen et al.,…”
Kovalenko, V., Александровна, Х. Е., Рзаев, Д. А., & Medvedev, S. P. (2017) · Genes and Cells · doi:10.23868/201707012 · Cited by 4
Vajhøj, C., Schmid, B., Alik, A., Melki, R., Fog, K., Holst, B., & Stummann, T. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261536 · Cited by 5
Alpha-Synuclein co-pathology in Alzheimer’s Disease drives tau accumulationPreprint
Struebing, F. L., Song, X., Vecchi, T. D., Widmann, J., Fierli, F., Ruf, V., Tang, Q., Arzberger, T., Roeber, S., Koeglsperger, T., et al. (2025) · Research Square · doi:10.1101/2025.01.24.634706 · Cited by 7
Gorgogietas, V. A., Weiss, A., Cousin, L., Hoffmann, D., Schmitt, K., Ogier, A., Barbuti, P. A., Santos, B. F. R., Boussaad, I., Wittich, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-14735-0 · Cited by 3
Bury, A. G., Olejnik, A., Tocco, C., Saurat, N. G., Stephen, E., Hockemeyer, D. F., Schwamborn, J. C., Studer, L., Mastroberardino, P. G., Bolognin, S., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01137-2 · Cited by 6
“Fibroblasts can also be cultured from patients and age-matched donors and retain age-associated characteristics, although many features of the PD pathophysiology are less pronounced or not expressed in fi broblasts compared to neurons 18,80 – 82 .”
Self-citationWang, Y., Wang, Z., Wang, L., Sun, Y., Song, H., Cheng, X., He, X., Gao, Z., & Sun, Y. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70027 · Cited by 4
Baud, A., Little, D., Teo, Q. W., Heywood, W., Gissen, P., & Mills, K. A. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00831 · Cited by 4
Modern Ways of Obtaining Stem Cells
Çağlayan, Ş., Ahrens, T. D., Cieślar‐Pobuda, A., & Staerk, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812258-7.00003-4 · Cited by 3
Ndayisaba, A., Herrera-Vaquero, M., Wenning, G. K., & Stefanova, N. (2019) · Clinical Autonomic Research · doi:10.1007/s10286-019-00614-y · Cited by 4
Human Pluripotent Stem Cells Modeling Neurodegenerative Diseases
Nat, R., Eigentler, A., & Dechant, G. (2013) · InTech eBooks · doi:10.5772/55772 · Cited by 5
“showed that the levels of α-Synuclein protein were increased in the dopaminergic population derived from patients, compared to the healthy controls [88], while Pluripotent Stem Cells 486”
BackgroundResultThe application of iPSCs in Parkinson’s disease
Nielsen, J. J. J., Lillethorup, T. P., Glud, A. N., Sørensen, J. C. H., & Orłowski, D. (2020) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2020-024 · Cited by 3
“The aged hiPSC‑derived SNCA‑Tri neurons con‑ tained more α‑synuclein aggregates per cell compared to DA neurons at the Juvenile stage.”
BackgroundInfluentialEditorial: Pathogenic templating proteins in Neurodegenerative Disease
Volpicelli‐Daley, L. A., & Brundin, P. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.11.004 · Cited by 3
Targett, I. L., Pring, K., Valiente, A. I. M., Qualtrough, D., Conway, M. E., Crompton, L. A., & Craig, T. J. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05367-6 · Cited by 2
“The hiPSC (nas2) cell line was obtained from the Devine lab [34], and forebrain neural stem cells (fbNSCs) were generated in Jon Lane’s lab (University of Bristol) [35–37]. fbNSCs were maintained in N2B27 medium containing: DMEM/F-12, neurobasal (Gibco, 21103049), B27 (Gibco, 17504044), N2 (Gibco,…”
Bergua, I. Y., Boussaad, I., Petkovski, E., Landoulsi, Z., Krüger, R., & Arena, G. (2026) · Stem Cell Research · doi:10.1016/j.scr.2026.103909 · Cited by 2
Ávila-Pacheco, J., Sauli, G., Fonseca‐Ornelas, L., Cirka, H., Kumari, D., Hazo, M., Jeanfavre, S., Vendramini, P. H., Muratore, C., Clish, C. B., et al. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00110-8 · Cited by 2
Ali, S., Mukherjee, S., Goel, D., Ghosh, A., & Faruq, M. (2023) · Springer eBooks · doi:10.1007/978-981-99-3848-3_10 · Cited by 2
Lange, S., Wray, S., Devine, M. J., Matarín, M., & Hardy, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-58244-3_13 · Cited by 7
Self-citationMisfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases
Kumar, S., Narayanan, K., Mishra, S., Padmanabhan, P., Radda, G. K., & Gulyás, B. Z. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1232-4 · Cited by 2
West, S., Natalwala, A., Dolt, K. S., Lamont, D. J., McMillan, M., Luk, K. C., Mashimo, T., & Kunath, T. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf224 · Cited by 3
“Unlike the SNCA triplication mutation, which doubles α Syn levels, 43 we found that RNA and protein levels of total α Syn were similar in Snca G51D/G51D and control rats.”
Self-citationVerde, C. D., Jayanti, S. D., El-Khobar, K. E., Stanford, J. A., Tiribelli, C., & Gazzin, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146881 · Cited by 3
“Nevertheless, as for the other PD-linked mutations, iPSCs derived from patients with SNCA variants are powerful tools for developing personalized medicine approaches [316,386].”
Modeling Parkinson Disease with Human Induced Pluripotent Stem Cells
Lü, J. (2014) · Cloning & Transgenesis · doi:10.4172/2168-9849.1000e113 · Cited by 2
“LRRK2 (G2019S) mutant iPSC-derived dopaminergic neurons show increased expression of key oxidative stress-response genes and a-synuclein protein, dysregulation of CPNE8, MAP7,UHRF2, ANXA1 and CADPS2, increased ERK phosphorylation, more sensitive to stress, and morphological alterations[24-26].”
BackgroundUtility of Human Stem Cells for Drug Discovery
Chintawar, S., Graf, M. R., & Cader, M. Z. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782620136-00162 · Cited by 2
Choi, W.-Y., Hwang, J.-H., Lee, J.-Y., Cho, A., Lee, A., Jung, I., Cho, S., Kim, L. K., & Kim, Y.-J. (2020) · Genes · doi:10.3390/genes11101176 · Cited by 2
“Of special interest are neural progenitor cells (NPCs)—precursor cells from which neurons are generated for applications in diseases such as Parkinson’s disease [2], Alzheimer’s disease [3,4], schizophrenia [5] and spinal injury [6].”
Generation of a CHIP isogenic human iPSC-derived cortical neuron model for functional proteomics
Dias, C., Nita, E., Faktor, J., Hernychová, L., Kunath, T., & Ball, K. L. (2022) · STAR Protocols · doi:10.1016/j.xpro.2022.101247 · Cited by 2
“This may be a challenge when looking to differentiate an isogenic set of iPSC lines, where comparable differentiation potential is a prerequisite (Vitale et al., 2012); despite being potentially challenging, this is possible, as demonstrated in (Dias et al., 2021)).”
BackgroundMethodSelf-citationNatalwala, A., Behbehani, R., Yapom, R., & Kunath, T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.898560 · Cited by 2
“cortical differentiation the hiPSC line, AST18, containing an SNCA triplication mutation exhibited a 3-fold increase in αSyn expression compared to a control hiPSC line, NAS2, derived from a 1degree relative (Devine et al., 2011) (Figure 3D).”
BackgroundInfluentialSelf-citationEmerging Methods in Modeling Brain Development and Disease with Human Pluripotent Stem Cells
Allen, G. E., Dhanda, A. S., & Julian, L. M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2409-8_20 · Cited by 2
CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review
Khatibi, S., Sahebkar, A., & Aghaee‐Bakhtiari, S. H. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200621161610 · Cited by 3
Loss of PAX6 alters the excitatory to inhibitory neuronal ratio in human cerebral organoids
Chan, W. K., Abdulla, S., Zhao, L., Negro, D., Munro, V. M., Thomson, S. R., Marshall, H., Kozić, Z., Brown, M., Barbato, M., et al. (2026) · Development · doi:10.1101/2023.07.31.551262 · Cited by 3
[IPS an ethical paradigm for biomedical research].
Escalona, J. A. G. (2013) · Cuadernos de bioética/Cuadernos de bioética · Cited by 2
Lieberman, R., Elnaggar, K., Jesseman, K., DeFrancisco, S., DeGouveia, K. L., Suneby, E. G., Wu, H., Rojas, L. A., & Graef, J. D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.15.516591 · Cited by 2
Li, Y., Sun, T., Hu, S., Xu, H., Zhang, T., Liu, J., Lu, S., Wang, B., & Guo, D. (2025) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.70098 · Cited by 1
“Additionally, iPSCs technology provides valuable in vitro models for disease research (Kawamura et al. 2012), drug testing (Xu and Zhong 2013), and gene therapy evaluation (Devine et al. 2011).”
Tan, J. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au27125 · Cited by 1
Modelling Neurodegenerative Diseases Using Human Pluripotent Stem Cells
Hall, V. J. (2016) · InTech eBooks · doi:10.5772/63521 · Cited by 1
Metadata
- Authors
- Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., Schapira, A. H., Gwinn, K., Hardy, J., Lewis, P. A., & Kunath, T.
- Affiliations
- MRC Centre for Regenerative Medicine (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Roslin Institute (GB)
- University of Tsukuba (JP)
- Baylor College of Medicine (US)
- Corresponding author
- Devine, Michael J.
- Kunath, Tilo
- ORCID
- Venue
- Nature Communications
- Published
- 2011-08-23
- Volume
- 2
- Issue
- 1
- Pages
- 440-440
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3265381
- OpenAlex
- W1985010554
- Cited by
- 486
- References
- 61
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 27 · 2023: 25 · 2022: 40 · 2021: 26 · 2020: 43 · 2019: 24 · 2018: 46 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 29 · 2013: 32 · 2012: 48
- FWCI
- 22.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- ASEP (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- University of Dundee
- Wellcome Trust (089698)
- Parkinson's UK (K-0911, G-4046, G-0907, F1002), F-0902)
- Brain Research Trust
- University of Sheffield
- Medical Research Council (MC_G1000735)
- Biotechnology and Biological Sciences Research Council (BBS/E/R/00001627, BBS/E/R/00001601)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, SNCA triplication, familial Parkinson's disease, midbrain dopaminergic neurons, disease modeling, neurodegeneration, multiple system atrophy, dementia with Lewy bodies, alpha-synuclein overexpression
- MeSH terms
- Cell Differentiation, Cells, Cultured, Humans, Neurons, Parkinson Disease, Gene Dosage, alpha-Synuclein, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.